According to the classical paradigm, CCR7 is a homing chemokine receptor that grants
normal lymphocytes access to secondary lymphoid tissues such as lymph nodes or
spleen. As such, in most lymphoproliferative disorders, CCR7 expression correlates with
nodal or spleen involvement. Nonetheless, recent evidence suggests that CCR7 is more
than a facilitator of lymphatic spread of tumor cells. Here, we review published data to
catalogue CCR7 expression across blood cancers and appraise which classical and novel
roles are attributed to this receptor in the pathogenesis of specific hematologic
neoplasms. We outline why novel therapeutic strategies targeting CCR7 might provide
clinical benefits to patients with CCR7-positive hematopoietic tumors.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:84397 |
| Date | 30 March 2023 |
| Creators | Cuesta-Mateos, Carlos, Terrón, Fernando, Herling, Marco |
| Publisher | Frontiers Research Foundation |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 2234-943X, 736758 |
Page generated in 0.0023 seconds